Drug
P 3073
P 3073: highest development phase Phase 3, developed by Almirall. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| P-3073 (calcipotriene 0.005%) NCT03079973 | Phase 3 | Nail Psoriasis |
Latest
No recent events.
Follow P 3073 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.